Stealth BioTherapeutics (MITO) Scheduled to Post Earnings on Thursday

Stealth BioTherapeutics (NASDAQ:MITO) is scheduled to be releasing its earnings data before the market opens on Thursday, November 14th. Analysts expect Stealth BioTherapeutics to post earnings of ($0.04) per share for the quarter.

Stealth BioTherapeutics (NASDAQ:MITO) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.04. On average, analysts expect Stealth BioTherapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of MITO traded up $0.32 during midday trading on Tuesday, reaching $6.79. The stock had a trading volume of 7,690 shares, compared to its average volume of 26,118. The firm’s 50 day moving average price is $6.43 and its 200-day moving average price is $10.48. The company has a market capitalization of $226.64 million and a P/E ratio of -4.82. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.13 and a quick ratio of 2.13. Stealth BioTherapeutics has a 52 week low of $4.97 and a 52 week high of $20.99.

A number of brokerages have recently issued reports on MITO. Cantor Fitzgerald began coverage on Stealth BioTherapeutics in a research report on Friday, September 27th. They set an “overweight” rating and a $18.00 target price on the stock. Zacks Investment Research raised Stealth BioTherapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Jefferies Financial Group set a $9.00 target price on Stealth BioTherapeutics and gave the stock a “hold” rating in a research report on Tuesday, October 15th. Nomura set a $28.00 target price on Stealth BioTherapeutics and gave the stock a “buy” rating in a research report on Friday, October 18th. Finally, HC Wainwright set a $21.00 target price on Stealth BioTherapeutics and gave the stock a “buy” rating in a research report on Friday, October 18th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $21.86.

About Stealth BioTherapeutics

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

Featured Story: How does a reverse stock split work?

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.